In Part 1, participants in Cohort A (n=465), without Type 2 diabetes, were assigned to one of four monthly fixed dose arms (placebo, 140 mg, 280 mg, 420 mg) or an 8-week 420 mg dose arm
Product Highlights & Quick Facts Product Type: Blended Research Peptide (GHRH + GHRP) Total Content: 10mg per vial (typically blended in a 1:1 or specific ratio [verify with brand/source]) Format: Lyophilized (freeze-dried) white powder Purity Standard: $\ge$ 98% (verified via HPLC and Mass Spectrometry) Intended Use: In vitro and in vivo laboratory research purposes only Storage Requirements: Store at -20C for long-term stability
Several factors contribute to these elevated costs: Patent protection Most GLP-1 medications are still under patent, preventing generic competition Manufacturing complexity These are biologic medications that require specialized production processes Research and development costs Pharmaceutical companies invest heavily in clinical trials and regulatory approval Market positioning These medications are often priced as premium treatments Without insurance coverage, patients face the full retail price, which can make these medications financially inaccessible for many people who need them
The concentration of TTs was significantly lower in Glc (10%) and Glc + amlodipine (4%) versus BSA, while the level of Glc + NAC (+ 11%) was markedly higher in comparison with BSA (Fig
